Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

  1. Jiménez-Vicente, C.
  2. Esteve, J.
  3. Baile-González, M.
  4. Pérez-López, E.
  5. Martin Calvo, C.
  6. Aparicio, C.
  7. Oiartzabal Ormategi, I.
  8. Esquirol, A.
  9. Peña-Muñoz, F.
  10. Fernández-Luis, S.
  11. Heras Fernando, I.
  12. González-Rodríguez, A.P.
  13. López-García, A.
  14. López-Lorenzo, J.L.
  15. Torrado, T.
  16. Sáez Marín, A.J.
  17. Acosta Fleytas, C.
  18. García, L.
  19. Villar, S.
  20. Filaferro, S.
  21. Balsalobre, P.
  22. Pascual Cascón, M.J.
  23. Salas, M.Q.
Journal:
Blood Cancer Journal

ISSN: 2044-5385

Year of publication: 2025

Volume: 15

Issue: 1

Type: Article

DOI: 10.1038/S41408-025-01223-X GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus